Tests (Medical)

Subterms

    Latest story

    100 Shares60 Views

    A Blood Test for Alzheimer’s: What to Know

    by

    The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.A blood test that can help diagnose Alzheimer’s disease has received clearance from the Food and Drug Administration. This is a step toward a goal of scientists and doctors to one day be able to diagnose a confounding illness with the prick of a finger. But there is still a long way to go.Here is what to know:What is the test, and how should it be used?The test, manufactured by Fujirebio Diagnostics, is intended to be used only by specialists in Alzheimer’s, the F.D.A. said. Its mouthful of a name — Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio — describes what the test measures: levels of two proteins, amyloid and tau, that are hallmarks of Alzheimer’s disease.In people who develop Alzheimer’s, amyloid begins to accumulate and form plaques in the brain more than 20 years before any symptoms of cognitive impairment. Tau accumulates later, forming tangles in the brain, and is much more closely correlated with cognitive decline.Can people who don’t have memory problems take the blood test?No. The F.D.A., and Alzheimer’s experts, emphasized that the blood test should be given only to people who are already experiencing cognitive decline and are ages 55 and older. Moreover, it should not be used on its own to diagnose or to rule out Alzheimer’s.“Other clinical evaluations or additional tests should be used for determining treatment options,” the F.D.A. said in a statement, adding that “the results must be interpreted in conjunction with other patient clinical information.”The current gold standard for diagnosing Alzheimer’s still involves either imaging using PET scans, which are expensive, or spinal taps, which are invasive. The blood test can help flag the presence of the Alzheimer’s-related proteins, and doctors might then order confirmatory testing with one of the other methods.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    More stories

    • 100 Shares87 Views

      in Elections

      Elizabeth Holmes’s Partner Has a New Blood-Testing Start-Up

      by

      Billy Evans has two children with the Theranos founder, who is in prison for fraud. He’s now trying to raise money for a testing company that promises “human health optimization.”Elizabeth Holmes is in prison for defrauding investors through her blood-testing company, Theranos. In the meantime, her partner is starting one of his own.Billy Evans, who has two children with Ms. Holmes, is trying to raise money for a company that describes itself as “the future of diagnostics” and “a radically new approach to health testing,” according to marketing materials reviewed by The New York Times.If that sounds familiar, it’s because Theranos similarly aimed to revolutionize diagnostic testing. The Silicon Valley start-up captured the world’s attention by claiming, falsely as it turned out, to have developed a blood-testing device that could run a slew of complex lab tests from a mere finger prick.Mr. Evans’s company is named Haemanthus, which is a flower also known as the blood lily. It plans to begin with testing pets for diseases before progressing to humans, according to two investors pitched on the company who spoke on the condition of anonymity because they had agreed to keep the plans secret. Mr. Evans’s marketing materials, which lay out hopes to eventually raise more than $50 million, say the ultimate goal is nothing short of “human health optimization.”The Haemanthus testing device.HaemanthusA photo provided to potential investors of the start-up’s prototype bears more than a passing physical resemblance to Theranos’s infamous blood-testing machine, variously known as the Edison or miniLab. The device that Mr. Evans’s company is developing is a rectangular contraption with a door, a digital display screen and what the investor materials describe as tunable lasers inside.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 113 Shares170 Views

      in Elections

      F.D.A. Approves First At-Home Alternative to the Pap Smear

      by

      The tool will allow women to screen for HPV, which causes almost all cases of cervical cancer, without visiting a doctor.The Food and Drug Administration approved the United States’ first at-home cervical cancer screening tool on Friday, a decision that stands to give women an accessible alternative to Pap smears, which many find painful or traumatic.The new test, made by Teal Health, involves swabbing the vagina with a spongelike tool rather than inserting a speculum and scraping cells from the cervix, as doctors do in Pap smears.Similar vaginal tests were approved last year for use in medical offices. But the at-home version could help women who have trouble finding, traveling to or making time for an in-person appointment.The approval is a result of a process that began with the discovery decades ago that the human papillomavirus, commonly known as HPV, causes almost all cervical cancer cases, and that people who don’t have the virus are at virtually no risk.Armed with that information, many doctors started testing Pap smear samples for HPV in addition to analyzing cervical cells under a microscope. Some medical authorities shifted to recommend HPV testing as the primary screening method, which opened the door for vaginal tests, because the virus can be detected in vaginal as well as cervical cells.Cervical cancer experts told The New York Times that the evidence for at-home testing was strong, and studies show it to be about as accurate as Pap smears.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 150 Shares119 Views

      in Elections

      Drugs Have Uses We Can’t Imagine. He’s Using A.I. to Find Them.

      by

      A little over a year ago, Joseph Coates was told there was only one thing left to decide. Did he want to die at home, or in the hospital?Coates, then 37 and living in Renton, Wash., was barely conscious. For months, he had been battling a rare blood disorder called POEMS syndrome, which had left him with numb hands and feet, an enlarged heart and failing kidneys. Every few days, doctors needed to drain liters of fluid from his abdomen. He became too sick to receive a stem cell transplant — one of the only treatments that could have put him into remission.“I gave up,” he said. “I just thought the end was inevitable.”But Coates’s girlfriend, Tara Theobald, wasn’t ready to quit. So she sent an email begging for help to a doctor in Philadelphia named David Fajgenbaum, whom the couple met a year earlier at a rare disease summit.By the next morning, Dr. Fajgenbaum had replied, suggesting an unconventional combination of chemotherapy, immunotherapy and steroids previously untested as a treatment for Coates’s disorder.Within a week, Coates was responding to treatment. In four months, he was healthy enough for a stem cell transplant. Today, he’s in remission.The lifesaving drug regimen wasn’t thought up by the doctor, or any person. It had been spit out by an artificial intelligence model.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 125 Shares189 Views

      in Elections

      F.D.A. Expands Access to Clozapine, a Key Treatment for Schizophrenia

      by

      Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies.The Food and Drug Administration has taken a crucial step toward expanding access to the antipsychotic medication clozapine, the only drug approved for treatment-resistant schizophrenia, among the most devastating of mental illnesses.The agency announced on Monday that it was eliminating a requirement that patients submit blood tests before their prescriptions can be filled.Clozapine, which was approved in 1989, is regarded by many physicians as the most effective available treatment for schizophrenia, and research shows that the drug significantly reduces suicidal behavior. Clozapine is also associated with a rare side effect called neutropenia, a drop in white blood cell counts that, in its most severe form, can be life-threatening.In 2015, federal regulators imposed a regimen known as risk evaluation and mitigation strategies, or REMS, that required patients to submit to weekly, biweekly and monthly blood tests that had to be uploaded onto a database and verified by pharmacists.Physicians have long complained that, as a result, clozapine is grossly underutilized.Dr. Frederick C. Nucifora, director of the Adult Schizophrenia Clinic at the Johns Hopkins School of Medicine, said he believed that around 30 percent of patients with schizophrenia would benefit from clozapine — far more than the 4 percent who currently take it.“I have had many patients who were doing terribly, who struggled to function outside the hospital, and cycled through many medications,” he said. “If they go on clozapine, they really tend to not be hospitalized again. I’ve had people go on to finish college and work. It’s quite remarkable.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 150 Shares129 Views

      in Elections

      Trump Secretly Stayed in Touch With Putin After Leaving Office, Book Says

      by

      Former President Donald J. Trump has secretly spoken with President Vladimir V. Putin of Russia as many as seven times since leaving office, even as he was pressuring Republicans to block military aid to Ukraine to fight Russian invaders, according to a new book by the journalist Bob Woodward.The book, titled “War” and scheduled to be published next week, describes a scene in early 2024 at Mar-a-Lago, Mr. Trump’s estate in Florida, when the former president ordered an aide out of his office so he could conduct a phone call with Mr. Putin. The unidentified aide said the two may have spoken a half-dozen other times as well since Mr. Trump left the White House.The book also reports that Mr. Trump, while still in office early during the Covid-19 pandemic in 2020, secretly sent Mr. Putin what were then rare tests for the virus for the Russian’s personal use. Mr. Putin, who has been described as particularly anxious about being infected at the time, urged Mr. Trump to not publicly reveal the gesture because it could damage the American president politically. “I don’t want you to tell anybody because people will get mad at you, not me,” Mr. Putin reportedly told him.The disclosures raise new questions about Mr. Trump’s relationship with Mr. Putin just weeks before an election that will determine whether the former president will reclaim the White House. A copy of the book was obtained by The New York Times. The Washington Post, where Mr. Woodward has worked for more than half a century, and CNN, where he often appears as a commentator, also reported on the book on Tuesday.Mr. Trump’s campaign dismissed Mr. Woodward’s book by assailing the author with typically personal insults — “a total sleazebag,” “slow, lethargic, incompetent and overall a boring person with no personality” — without addressing any of the specifics reported in it.“None of these made-up stories by Bob Woodward are true and are the work of a truly demented and deranged man who suffers from a debilitating case of Trump Derangement Syndrome,” Steven Cheung, the campaign communications director, said in the statement. Mr. Cheung said Mr. Trump did not give Mr. Woodward access for the book and noted that the former president was suing the author over a previous book.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 138 Shares199 Views

      in Elections

      Trump prometió hacer público su historial médico pero sigue sin hacerlo

      by

      Si vuelve a ser elegido, se convertirá en el presidente de mayor edad al final de su mandato. Sin embargo, se niega a revelar incluso la información médica básica.[Estamos en WhatsApp. Empieza a seguirnos ahora]Como candidato presidencial en 2015, Donald Trump se negó a publicar su historial médico, ofreciendo en su lugar una carta de cuatro párrafos de su médico personal en la que proclamaba que sería “la persona más sana jamás elegida para la presidencia”.En 2020, cuando estuvo hospitalizado por COVID-19 y se presentaba a la reelección, los médicos de Trump dieron una información mínima sobre su estado, que, según se supo más tarde, fue mucho más grave de lo que dejó entrever las descripciones públicas.En 2024, días antes de convertirse en el candidato presidencial republicano oficial por tercera vez, fue rozado por una bala de un posible asesino, pero su campaña no celebró una sesión informativa sobre su estado, no publicó los registros hospitalarios ni puso a disposición a los médicos de urgencias que lo trataron para ser entrevistados.Ahora, a poco más de un mes de unas elecciones que podrían convertir a Trump, de 78 años, en la persona de mayor edad en ocupar la presidencia (82 años, 7 meses y 6 días cuando su mandato termine en enero de 2029), se niega a revelar incluso la información más básica sobre su salud.Si gana, Trump podría entrar en el Despacho Oval con una serie de problemas potencialmente preocupantes, según los expertos médicos: factores de riesgo cardíaco, posibles secuelas del intento de asesinato de julio y el deterioro cognitivo que se produce de forma natural con la edad, entre otros.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 150 Shares99 Views

      in Elections

      Do You Have Healthy Brain Habits? Take This Quiz to Find Out.

      by

      What can I do to take good care of my brain and lower my risk for a neurological disease? That’s the No. 1 question neurologist Dr. Jonathan Rosand hears from his patients (and their family members) at the Massachusetts General Hospital McCance Center for Brain Health. To help answer it, he and his colleagues, with […] More

    • 100 Shares119 Views

      in Elections

      Tell us: Have you been forgoing Covid tests?

      by

      It’s the fifth summer of Covid, and most people seem eager to move on. We want to understand the pervasiveness of the ignorance-is-bliss attitude.Covid cases are surging, but in contrast to summers past, our lives seem to be carrying on with all of their scheduled programming.Covid is still a serious threat to people who are immunocompromised or elderly, but for many others, a positive Covid case seems to be regarded much like the common cold of the before times, and some are abandoning their once-meticulous methods of testing and isolation in favor of a more laissez-faire attitude.The Times is trying to assess how people are thinking about their own transition into a life where the disease is by some standards endemic. On days when you haven’t felt very well, have you bothered to test for Covid, or decided it didn’t really matter what respiratory condition was behind it? If someone in your household has come down with Covid, did you go to work, school or the gym anyway, despite your exposure? Have you found yourself purposely skipping a Covid test for fear of having your social or vacation plans canceled?Please respond by Monday, Aug. 19. We won’t publish any part of your response without following up with you first, verifying your information and hearing back from you. And we won’t share your contact information outside the Times newsroom or use it for any reason other than to get in touch with you. More